Contents
Market Overview
Italy remains one of Europe’s most tightly controlled medical cannabis markets, operating under a government-monopolised system that regulates import, distribution, and domestic cultivation.
The estimated market size for 2024 stands at over €49 million, with projections indicating growth to €XXX million by 2029 (Prohibition Partners Market Sizing Forecasts, 2025–2029). Despite this, market expansion has stagnated in recent years due to rigid state oversight, limited product diversity, and minimal regulatory reform.
The Italian Ministry of Defence maintains sole responsibility for domestic cultivation, producing approximately 100 kilograms annually of a single proprietary strain known as FM2. Imports remain essential to meet patient demand, with Bedrocan (Netherlands) acting as the primary supplier under a long-term supply agreement renewed periodically by the government.
Although Italy was once considered a leader in patient access within Southern Europe, a lack of policy innovation has resulted in limited therapeutic options and slow industry development. Prescribing procedures, patient pathways, and physician education have remained unchanged for nearly a decade.
Regulatory Framework
Italy legalised the prescription of medical cannabis in 2015 through a ministerial decree, which authorised magistral cannabis preparations to be dispensed through pharmacies.
The framework delegates implementation and reimbursement policy to regional health authorities, resulting in significant variation between regions. Some regions, such as Lombardy and Veneto, maintain structured access programmes, while others have no practical implementation at all.
Key regulatory features include:
- Central government control over imports, licensing, and production.
- Military-controlled cultivation at the Stabilimento Chimico Farmaceutico Militare (SCFM) in Florence.
- Regional variation in access, reimbursement, and eligible conditions.
- Magistral compounding as the primary method of preparation and dispensing.
While Italy’s framework technically allows for imports from multiple suppliers, in practice, the government grants exclusive tenders—most consistently to Bedrocan—to maintain supply stability and pricing control.oice.ed by the European Medicines Agency, such as Sativex, which remains available under a restricted prescription pathway.
Patient Access
Who Can Prescribe?
Patient access depends on whether prescriptions fall under private or public healthcare:
- Private prescriptions: Any licensed physician may prescribe cannabis for any condition supported by scientific evidence, provided conventional therapies have failed or caused adverse effects.
- Public prescriptions (reimbursed): Access is restricted by regional guidelines, which define eligible conditions, approved specialists, and available products. A specialist therapeutic plan is mandatory, though general practitioners may issue renewals.
Treatable Pathologies:
- Private (paid) prescriptions: Any pathology supported by clinical evidence.
- Public (reimbursed) prescriptions: Typically limited to:
- Chronic pain
- Spasticity (e.g., multiple sclerosis)
- Chemotherapy-induced nausea and vomiting
- Muscle spasms
- Anorexia or cachexia
- Glaucoma
- Tourette syndrome
Reimbursement:
Treatment is reimbursed only under public healthcare, and eligibility depends on regional frameworks. Patients accessing cannabis privately must pay out-of-pocket.m, but some private insurers may cover the cost on a case-by-case basis. Patients typically bear the full out-of-pocket cost, though pharmacy prices are relatively stable due to state-set wholesale rates.
Products & Prices
The Italian medical cannabis market offers a limited range of flower and extract products, primarily sourced through imports and magistral preparations.
Available Flower Strains:
- Bedrocan
- Bediol
- Bedica
- Bedrolite
- Bedrobinol (authorised but not currently available)
- FM2 (cultivated by the Italian military)
- Hindu Kush (Linneo Health)
All flower products are sold at a fixed price of €9 per gram + VAT.
Available Extract Products:
A total of 10 extract formulations are currently available in Italy, produced by Farmalabor, Avextra, and Tilray. Pharmacies are required to sell these extracts at cost price, with 0% margin, meaning there is no retail profit incentive.
Farmalabor Extracts:
- 15% THC
- 1% THC / 1% CBD
- 2.5% THC
- 2% THC
- 1% THC
- 5% CBD
Avextra/Fargon Extracts:
- 1% THC / 1% CBD
Tilray Extracts:
- T5C20 (5 mg/ml THC, 20 mg/ml CBD)
- T25 (25 mg/ml THC)
- THC10:10 (10 mg/ml THC, 10 mg/ml CBD)
Imports & Exports
The Italian market is heavily reliant on imported cannabis products. While multiple suppliers have participated in government tenders over the years, Bedrocan remains the only consistent long-term importer, accounting for roughly 90% of medical cannabis used in treatment by volume.
Other producers have periodically supplied the market via short-term contracts, but these arrangements are typically limited in scale and duration. Italy does not currently export medical cannabis.
Domestic Production
Domestic cultivation is entirely government-controlled, managed by the Italian military at the SCFM facility in Florence. Production remains fixed at approximately 100 kilograms per year, focused on the FM2 strain.
Despite the government’s stated goal of achieving domestic self-sufficiency, annual production targets have never been met. Imports have therefore increased steadily since 2018 to fill supply gaps.
The absence of private sector participation, coupled with bureaucratic procurement processes, has contributed to persistent supply shortages and limited innovation.
Outlook
Italy’s medical cannabis market continues to operate within an outdated and rigid framework, inhibiting both patient access and industry growth. While demand remains stable, the system’s state monopoly, lack of new tenders, and minimal diversification prevent meaningful market development.
Reform efforts are unlikely in the short term, though increased EU coordination and patient advocacy may eventually prompt a reassessment of Italy’s restrictive approach.
For now, Italy remains a highly centralised, import-dependent market, with patient care and innovation constrained by administrative inertia.
